

US virus numbers drop, but race against new strains heats up

January 25 2021, by Jonathan Drew and Michael Kunzelman



In this Jan. 23, 2021, file photo, Dorothy Kade, left, holds the hand of her husband, Walter Kade Jr., as they wait in the observation room after he received a COVID-19 vaccine at the VA Medical Center, in Philadelphia. (Tyger Williams/The Philadelphia Inquirer via AP, File)

Coronavirus deaths and cases per day in the U.S. dropped markedly over



the past couple of weeks but are still running at alarmingly high levels, and the effort to snuff out COVID-19 is becoming an ever more urgent race between the vaccine and the mutating virus.

The government's top infectious-disease expert, Dr. Anthony Fauci, said the improvement in numbers around the country appears to reflect a "natural peaking and then plateauing" after a holiday surge, rather than the arrival of the vaccine in mid-December.


The U.S. is recording just under 3,100 deaths a day on average, down from more than 3,350 less than two weeks ago. New cases are averaging about 170,000 a day after peaking at almost 250,000 on Jan. 11. The number of hospitalized COVID-19 patients has fallen to about 110,000 from a high of 132,000 on Jan. 7.

States that have been hot spots in recent weeks such as California and Arizona have shown similar improvements during the same period.

On Monday, California lifted regional stay-at-home orders in favor of county-by-county restrictions and ended a 10 p.m. curfew. The shift will allow restaurants and churches to resume outdoor operations and hair and nail salons to reopen in many places, though local officials could maintain stricter rules.

Elsewhere, Minnesota school districts have begun bringing elementary students back for in-person learning. Chicago's school system, the nation's third-largest district, had hoped to bring teachers back Monday to prepare for students to return next month, but the teachers union has refused. Illinois announced that that more counties will be able to offer limited indoor dining.





Alex Gonzalez, 19, jumps rope on Angel's Point at Elysian Park as motorists wait in long lines to take a coronavirus test in a parking lot at Dodger Stadium, Monday, Jan. 4, 2021, in Los Angeles. Coronavirus deaths and cases per day in the U.S. dropped markedly over the past couple of weeks but are still running at alarmingly high levels, and the effort to snuff out COVID-19 is becoming an ever more urgent race between the vaccine and the mutating virus. (AP Photo/Ringo H.W. Chiu)

"I don't think the dynamics of what we're seeing now with the plateauing is significantly influenced yet—it will be soon—but yet by the vaccine. I just think it's the natural course of plateauing," Fauci told NBC's "Today."

Ali Mokdad, a professor of health metrics sciences at the University of



Washington, said that a predicted holiday surge was reduced by people traveling less than expected, and an increase in mask wearing in response to spikes in infections has since helped bring the numbers down.

Caitlin Rivers, an epidemiologist at the Johns Hopkins Center for Health Security, said too few people have been vaccinated so far for that to have had a significant impact on virus trends. She said she can't predict how long it will take for the vaccines' effects to be reflected in the numbers.

Rivers said she is concerned that the more contagious variants of the virus could lead to a deadly resurgence later this year.



In this Jan. 5, 2021, file photo, cars line up for COVID-19 testing outside Hard Rock Stadium in Miami Gardens, Fla. Coronavirus deaths and cases per day in



the U.S. dropped markedly over the past couple of weeks but are still running at alarmingly high levels, and the effort to snuff out COVID-19 is becoming an ever more urgent race between the vaccine and the mutating virus. (AP Photo/Wilfredo Lee, File)

"I think we were on track to have a good—or a better, at least—spring and summer, and I'm worried that the variants might be throwing us a curveball," she said.

Nationwide, about 18 million people, or less than 6% of the U.S. population, have received at least one dose of vaccine, including about 3 million who have gotten the second shot, according to the Centers for Disease Control and Prevention. Only slightly more than half of the 41 million doses distributed to the states by the federal government have been injected into arms, by the CDC's count.

The virus has killed over 419,000 Americans and infected more than 25 million, with a widely cited University of Washington model projecting the death toll will reach about 569,000 by May 1.

And health experts have warned that the more contagious and possibly more deadly variant sweeping through Britain will probably become the dominant source of infection in the U.S. by March. It has been reported in over 20 states so far. Another mutant version is circulating in South Africa.





People walk to a tent at a COVID-19 walk-up testing site on the Martin Luther King Jr. Medical Campus Thursday, Jan. 7, 2021, in Los Angeles. Coronavirus deaths and cases per day in the U.S. dropped markedly over the past couple of weeks but are still running at alarmingly high levels, and the effort to snuff out COVID-19 is becoming an ever more urgent race between the vaccine and the mutating virus. (AP Photo/Marcio Jose Sanchez)

The more the virus spreads, the more opportunities it has to mutate. The fear is that it will ultimately render the vaccines ineffective.

To guard against the new variants, President Joe Biden on Monday added South Africa to the list of more than two dozen countries whose residents are subject to coronavirus-related limits on entering the U.S.



Most non-U.S. citizens who have been to Brazil, Ireland, Britain and other European nations will be barred from entering the U.S. under the rules re-imposed by Biden after President Donald Trump had moved to relax them.

Fauci said scientists are already preparing to adjust COVID-19 vaccines to fight the mutated versions.

He said there is "a very slight, modest diminution" of the effectiveness of COVID-19 vaccines against those variants, but "there's enough cushion with the vaccines that we have that we still consider them to be effective" against both.



In this Jan. 23, 2021, file photo, registered Nurse Shyun Lin, left, gives Roberto Fisher, 72, the first dose of the COVID-19 vaccine at a pop-up vaccination site



in the William Reid Apartments in the Brooklyn borough of New York. Coronavirus deaths and cases per day in the U.S. dropped markedly over the past couple of weeks but are still running at alarmingly high levels, and the effort to snuff out COVID-19 is becoming an ever more urgent race between the vaccine and the mutating virus. (AP Photo/Mary Altaffer, Pool, File)



In this Jan. 6, 2021, file photo, health care workers prepare to inoculate a driver at a COVID-19 testing site, outside Hard Rock Stadium in Miami Gardens, Fla. Coronavirus deaths and cases per day in the U.S. dropped markedly over the past couple of weeks but are still running at alarmingly high levels, and the effort to snuff out COVID-19 is becoming an ever more urgent race between the vaccine and the mutating virus. (AP Photo/Wilfredo Lee, File)





In this Jan. 7, 2021, file photo, a technician distributes a test kit at a COVID-19 walk-up testing site on the Martin Luther King Jr. Medical Campus in Los Angeles. Coronavirus deaths and cases per day in the U.S. dropped markedly over the past couple of weeks but are still running at alarmingly high levels, and the effort to snuff out COVID-19 is becoming an ever more urgent race between the vaccine and the mutating virus. (AP Photo/Marcio Jose Sanchez, File)





In this Jan. 7, 2021, file photo, people line up at a COVID-19 walk-up testing site on the Martin Luther King Jr. Medical Campus in Los Angeles. Coronavirus deaths and cases per day in the U.S. dropped markedly over the past couple of weeks but are still running at alarmingly high levels, and the effort to snuff out COVID-19 is becoming an ever more urgent race between the vaccine and the mutating virus. (AP Photo/Marcio Jose Sanchez, File)

Moderna, the maker of one of the two vaccines being used in the U.S., announced on Monday that it is beginning to test a possible booster dose against the South African variant. Moderna CEO Stephane Bancel said the move was out of "an abundance of caution" after preliminary lab tests suggested its shot produced a weaker immune response to that variant.



The vaccine rollout in the U.S. has been marked by disarray and confusion, with states complaining in recent days about shortages and inadequate deliveries that have forced them to cancel mass vaccination events and tens of thousands of appointments.

New York Mayor Bill de Blasio said shortages are preventing the city from opening more large-scale vaccination sites.

"Here you have New York City ready to vaccinate at the rate of a half-million New Yorkers a week, but we don't have the vaccine to go with it," de Blasio said. "A lot of other places in the country are ready to do so much more."

© 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Citation: US virus numbers drop, but race against new strains heats up (2021, January 25) retrieved 1 May 2024 from https://medicalxpress.com/news/2021-01-virus-strains.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.